VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids

What You Should Know:– Owkin, an AI-biotech company specializing in precision medicine, and Proscia, a leader in AI-enabled pathology solutions, have announced a strategic partnership to improve MSI testing for colorectal cancer (CRC). This collaboration aims to enhance the efficiency and accessibility of MSI screening, ultimately leading to better patient outcomes.– Beyond MSI testing, Owkin and Proscia plan to collaborate on developing and commercializing additional AI solutions for research and diagnosis in oncology.The Importance of MSI Testing in Colorectal CancerMSI (Microsatellite Instability) is a genomic biomarker found in a significant portion of colorectal cancer patients. It plays a crucial role in guiding treatment decisions, as patients with MSI-high tumors often respond well to immunotherapy and may not benefit from traditional chemotherapy.Challenges in MSI TestingWhile universal MSI screening is recommended for CRC patients, current testing methods face challenges:Cost: Traditional methods like IHC, PCR, and NGS can be expensive.Traditional methods like IHC, PCR, and NGS can be expensive. Accessibility: Access to these tests may be limited in certain regions or healthcare settings.Access to these tests may be limited in certain regions or healthcare settings. Tissue Consumption: These tests can require significant amounts of tissue, which may be limited in some cases.These tests can require significant amounts of tissue, which may be limited in some cases. Interpretation: Results can sometimes be subjective and require expert interpretation.AI-Powered Solution for MSI ScreeningOwkin’s MSIntuit CRC v2 is an AI-powered solution designed to address these challenges

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit(R) CRC v2[1], a next-generation AI solution.